secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2024-03-15T23:59:59+00:00
Accession:  0001640334-24-000410
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria Bioscience appoints Nelson Cabatuan as CFO effective March 14, 2024
---------------------------------------------------------------------------

- Nelson Cabatuan, age 46, replaces temporary outsourced CFO services from NOW CFO.
- Base annual salary of US$198,000 with agreed annual increases of US$12,000 for first two years.
- Option grant of up to 200,000 common shares vested over three years; performance bonuses up to 35-50% of base.
- Exit compensation: upon sale of affiliate, 0.5%-1.0% of gross sale value; change-of-control triggers 12-14 months base salary.
- Cabatuan brings over 15 years biotech finance experience; previously SVP at Rain Oncology and VP at Rigel Pharmaceuticals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033424000410/0001640334-24-000410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033424000410/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-24-000410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer